Pedro Smith Pereira Ferraro
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Pedro Smith Pereira Ferraro has a total of 21 co-authors. Here are the top co-authors by number of shared publications:
- Amanda Yaeko Yamada
Centro de Bacteriologia, Instituto Adolfo Lutz, São Paulo, Brazil
2 shared publications - Carlos Henrique Camargo
Centro de Bacteriologia, Instituto Adolfo Lutz, São Paulo, Brazil
2 shared publications - Claudio Tavares Sacchi
Laboratório Estratégico, Instituto Adolfo Lutz, São Paulo, Brazil
2 shared publications - Karoline Rodrigues Campos
Laboratório Estratégico, Instituto Adolfo Lutz , São Paulo
2 shared publications - Ana Beatriz Nascimento Costa
Centro de Bacteriologia, Instituto Adolfo Lutz, São Paulo, Brazil
1 shared publication - Andreia Rodrigues de Souza
Bacteriology Center, Adolfo Lutz Institute, São Paulo/SP, Brazil
1 shared publication
Latest Publications
- 18 December 2025
- Published by Springer Nature in Antonie van Leeuwenhoek
- Vol. 119 (1) , 15
Unveiling the genomic and phenotypic landscape of Acinetobacter species from different environmental sources in Brazil
This study aimed to investigate the diversity of Acinetobacter spp. isolated from aquatic environments along the Brazilian coast, with a focus on environmental reservoirs of clinically relevant resistance genes. Twenty-three Acinetobacter isolates were recovered from marine animals, floating plastic, and surface water samples collected in two contrasting Brazilian regions: the heavily polluted Guanabara Bay (Rio de Janeiro) and the pristine Fernando de Noronha Archipelago (Pernambuco). Seven species were identified, with A. venetianus (n = 13) and A. johnsonii (n = 4) being the most frequent. Two A. johnsonii isolates carried the metallo-β-lactamase gene blaNDM-1, along with resistance to fluoroquinolones and carbapenems. Resistance to polymyxins and aminoglycosides was also observed in A. haemolyticus, A. baumannii, and A. modestus. ApaI-PFGE dendrogram and phylogenetic analyses based on single nucleotide position (SNPs) revealed high genetic diversity, and global comparisons placed the environmental isolates in lineages distinct from those commonly associated with healthcare-associated infections. This study highlights the diversity of Acinetobacter spp. in aquatic environments and their potential role as reservoirs of clinically important resistance genes, including blaNDM-1. By uncovering resistance mechanisms in environmental Acinetobacter strains, this work reinforces the relevance of environmental surveillance for One Health initiatives, particularly in regions with significant anthropogenic impact.
- 18 December 2025
- Published by Springer Nature in Antonie van Leeuwenhoek
- Vol. 119 (1) , 15
Unveiling the genomic and phenotypic landscape of Acinetobacter species from different environmental sources in Brazil
This study aimed to investigate the diversity of Acinetobacter spp. isolated from aquatic environments along the Brazilian coast, with a focus on environmental reservoirs of clinically relevant resistance genes. Twenty-three Acinetobacter isolates were recovered from marine animals, floating plastic, and surface water samples collected in two contrasting Brazilian regions: the heavily polluted Guanabara Bay (Rio de Janeiro) and the pristine Fernando de Noronha Archipelago (Pernambuco). Seven species were identified, with A. venetianus (n = 13) and A. johnsonii (n = 4) being the most frequent. Two A. johnsonii isolates carried the metallo-β-lactamase gene blaNDM-1, along with resistance to fluoroquinolones and carbapenems. Resistance to polymyxins and aminoglycosides was also observed in A. haemolyticus, A. baumannii, and A. modestus. ApaI-PFGE dendrogram and phylogenetic analyses based on single nucleotide position (SNPs) revealed high genetic diversity, and global comparisons placed the environmental isolates in lineages distinct from those commonly associated with healthcare-associated infections. This study highlights the diversity of Acinetobacter spp. in aquatic environments and their potential role as reservoirs of clinically important resistance genes, including blaNDM-1. By uncovering resistance mechanisms in environmental Acinetobacter strains, this work reinforces the relevance of environmental surveillance for One Health initiatives, particularly in regions with significant anthropogenic impact.
- Open Access
Genomics and Antimicrobial Susceptibility of Clinical Pseudomonas aeruginosa Isolates from Hospitals in Brazil
Pseudomonas aeruginosa, an opportunistic pathogen causing infections in immunocompromised patients, usually shows pronounced antimicrobial resistance. In recent years, the frequency of carbapenemases in P. aeruginosa has decreased, which allows use of new beta-lactams/combinations in antimicrobial therapy. Therefore, the in vitro evaluation of these drugs in contemporary isolates is warranted. We evaluated the antimicrobial susceptibility and genomic aspects of 119 clinical P. aeruginosa isolates from 24 different hospitals in Brazil in 2021–2022. Identification was performed via MALDI-TOF-MS, and antimicrobial susceptibility was identified through broth microdilution, gradient tests, or disk diffusion. Whole-genome sequencing was carried out using NextSeq equipment. The most active drug was cefiderocol (100%), followed by ceftazidime–avibactam (94.1%), ceftolozane–tazobactam (92.4%), and imipenem–relebactam (81.5%). Imipenem susceptibility was detected in 59 isolates (49.6%), and the most active aminoglycoside was tobramycin, to which 99 (83.2%) isolates were susceptible. Seventy-one different sequence types (STs) were detected, including twelve new STs described herein. The acquired resistance genes blaCTX-M-2 and blaKPC-2 were identified in ten (8.4%) and two (1.7%) isolates, respectively. Several virulence genes (exoSTUY, toxA, aprA, lasA/B, plcH) were also identified. We found that new antimicrobials are effective against the diverse P. aeruginosa population that has been circulating in Brazilian hospitals in recent years.
Open AccessGenomics and Antimicrobial Susceptibility of Clinical Pseudomonas aeruginosa Isolates from Hospitals in Brazil
Pseudomonas aeruginosa, an opportunistic pathogen causing infections in immunocompromised patients, usually shows pronounced antimicrobial resistance. In recent years, the frequency of carbapenemases in P. aeruginosa has decreased, which allows use of new beta-lactams/combinations in antimicrobial therapy. Therefore, the in vitro evaluation of these drugs in contemporary isolates is warranted. We evaluated the antimicrobial susceptibility and genomic aspects of 119 clinical P. aeruginosa isolates from 24 different hospitals in Brazil in 2021–2022. Identification was performed via MALDI-TOF-MS, and antimicrobial susceptibility was identified through broth microdilution, gradient tests, or disk diffusion. Whole-genome sequencing was carried out using NextSeq equipment. The most active drug was cefiderocol (100%), followed by ceftazidime–avibactam (94.1%), ceftolozane–tazobactam (92.4%), and imipenem–relebactam (81.5%). Imipenem susceptibility was detected in 59 isolates (49.6%), and the most active aminoglycoside was tobramycin, to which 99 (83.2%) isolates were susceptible. Seventy-one different sequence types (STs) were detected, including twelve new STs described herein. The acquired resistance genes blaCTX-M-2 and blaKPC-2 were identified in ten (8.4%) and two (1.7%) isolates, respectively. Several virulence genes (exoSTUY, toxA, aprA, lasA/B, plcH) were also identified. We found that new antimicrobials are effective against the diverse P. aeruginosa population that has been circulating in Brazilian hospitals in recent years.